
S&P/ASX All Ords Index (ASX: XAO) shares are down 1.6% to 8,961.6 points on Thursday.
Meanwhile, on The Bull, three experts give us their views on three ASX All Ords shares.
Let’s check them out.Â
Saluda Medical Inc (ASX: SLD)
The Saluda Medical share price is 40 cents, down 3.7% today and down 69% over 12 months.
Stuart Bromley from Medallion Financial Group has a buy call on this ASX All Ords healthcare share.
Bromley said:Â
Saluda makes the Evoke spinal cord stimulator, which automatically adjusts pain therapy in real time.
Results in full year 2026 were strong, in our view. Revenue of $US90.2 million was up 28 per cent on the prior corresponding period and ahead of upgraded guidance. US patient implants increased by 50 per cent in the fourth quarter of 2026.
With its newly approved CAP24 surgical paddle lead expanding the addressable US market by about 30 per cent, we believe SLD presents as an attractive buying opportunity for investors comfortable with potential share price volatility and risk.
Generation Development Group Ltd (ASX: GDG)
The Generation Development share price is $3.12, down 2.5% today and down 51% over 12 months.
Bromley has a hold rating on this ASX 200 financial share.
He said:
GDG operates a portfolio of growing financial services businesses, including Generation Life, Evidentia Group and Lonsec.
Total revenue of $178.7 million in full year 2026 was up 23 per cent on the prior corresponding period.
Underlying net profit after tax of $40.7 million grew 21 per cent, supported by growth of 37 per cent in funds under management and record group net inflows of $9.7 billion.
We believe GDG’s longer term growth opportunity remains intact.
Fletcher Building Ltd (ASX: FBU)
The Fletcher Building share price is $3.04, down 2.3% today and up 9% over 12 months.
Mark Elzayed from Vestra Capital has a sell rating on this ASX 200 industrials share.
Elzayed said:
The return to profitability reflected a combination of cost reductions, portfolio simplification, property sale gains and an improved performance across several core manufacturing businesses, rather than a broad based recovery in underlying construction demand.
Revenue of $NZ5.994 billion from continuing operations increased 7.3 per cent in full year 2026 when compared to the prior corresponding period.
Total net earnings attributable to shareholders reached $NZ228 million, compared to a loss of $NZ419 million in the prior year.
The return to profitability improves the balance sheet and reduces financial risk. But, in my view, a continuing recovery remains heavily dependent on building markets returning to normal in what I consider a most challenging underlying environment.
The post Buy, hold, sell: Generation Development, Fletcher Building, Saluda Medical shares appeared first on The Motley Fool Australia.
Should you invest $1,000 in Saluda Medical right now?
Before you buy Saluda Medical shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Saluda Medical wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Expert names 2 beaten-down ASX All Ords healthcare shares to buy today
- Here are the top 10 ASX 200 shares today
- Could this ASX healthcare stock really be set to rise 400%? Morgans thinks soÂ
- Top 3 beaten-down ASX 200 shares from August worth a second look
- The five worst-performing ASX 200 shares in August unmasked
Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Generation Development Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

